Management Team

Phillip Frost, M.D.

Dr. Frost became the CEO and Chairman of OPKO Health, Inc. on March 27, 2007, following the consummation of the merger of Acuity Pharmaceuticals, Inc., Froptix Corporation, and eXegenics, Inc.  Dr. Frost was named the Chairman of the Board of Teva Pharmaceutical Industries, Ltd. in March 2010, having served as Teva’s Vice Chairman since January 2006, Teva’s acquisition of IVAX Corporation.  Dr. Frost had served as Chairman of the Board of Directors and Chief Executive Officer of IVAX Corporation since 1987. He was Chairman of the Department of Dermatology at Mt. Sinai Medical Center of Greater Miami, Miami Beach, Florida from 1972 to 1986. He was also Chairman of the Board of Directors of Key Pharmaceuticals, Inc. from 1972 until the acquisition of Key Pharmaceuticals by Schering Plough Corporation in 1986.  In July 2006, Dr. Frost was also named Chairman of the Board of Ladenburg Thalmann Financial Services Inc., an investment banking, asset management, and securities brokerage firm providing services through its principal operating subsidiary, Ladenburg Thalmann & Co., Inc. He has been a director of Ladenburg Thalmann from 2001 until 2002, and again since 2004.  Dr. Frost also serves as Chairman of the Board of Directors of PROLOR Biotech, Inc., a development-stage biopharmaceutical company. He serves as a member of the Board of Trustees of the University of Miami and as a Trustee of the Scripps Research Institute, the Miami Jewish Home for the Aged, and the Mount Sinai Medical Center.  Dr. Frost is also a director of Castle Brands, a developer and marketer of premium brand spirits.  Dr. Frost previously served as a director for Continucare Corporation, Northrop Grumman Corp., Ideation Acquisition Corp., Protalix Bio Therapeutics, Inc., and SafeStitch Medical Inc. He also served as Governor and Co-Vice-Chairman of the American Stock Exchange.

Jane H. Hsiao, Ph.D., M.B.A.

Dr. Hsiao has served as Vice Chairman and Chief Technical Officer of the Company since May 2007.  She served as the Vice Chairman-Technical Affairs of IVAX from 1995 to January 2006, in addition to serving as Chairman, Chief Executive Officer and President of IVAX Animal Health, IVAX’s veterinary products subsidiary, from 1998 to 2006.  Dr. Hsiao has served as Chairman of the Board of Safestitch Medical, Inc. and of Non-Invasive Monitoring Systems, Inc., both medical device companies, since September 2007 and October 2008, respectively. She was named Interim Chief Executive Officer of Non-Invasive Monitoring Systems, Inc. in February 2012.  Dr. Hsiao is also a director of PROLOR Biotech, Inc., a development-stage biopharmaceutical company, Sorrento Therapeutics, Inc., a development-stage biopharmaceutical company, and Neovasc, Inc., a company developing and marketing medical specialty vascular devices.  Dr. Hsiao also previously served as a director for Protalix BioTherapeutics, Inc.

Steven D. Rubin

Mr. Rubin has served as Executive Vice President – Administration since May 2007 and as a director of the Company since February 2007.  He served as the Senior Vice President, General Counsel and Secretary of IVAX from August 2001 until September 2006.  He currently serves on the board of directors of Dreams, Inc., a vertically integrated sports licensing and products company; Safestitch Medical, Inc., a medical device company; Searchmedia Holdings, Ltd, a leading nationwide multi-platform media company and one of the largest operators of integrated outdoor billboard and in-elevator advertising networks in China; PROLOR Biotech, Inc., a development stage biopharmaceutical company; Kidville, Inc., which operates large, upscale facilities catering to newborns through five-year-old children and their families and offers a wide range of developmental classes for the children involved; Non-Invasive Monitoring Systems, Inc., a medical device company; Tiger X Medical, Inc., previously an early-stage orthopedic medical device company specializing in designing, developing, and marketing reconstructive joint devices and spinal surgical devices; Castle Brands, Inc., a developer and marketer of premium brand spirits; and Neovasc, Inc., a company developing and marketing medical specialty vascular devices.

Juan F. Rodriguez

Mr. Rodriguez was appointed Senior Vice President and Chief Financial Officer of the Company on July 16, 2012.  Immediately prior to joining OPKO, Mr. Rodriguez had served as a consultant to Cognitec Systems GmbH, a German software developer, since 2007.  From 1995 to 2007, prior to its acquisition by Abbott Laboratories, Mr. Rodriguez had worked with Kos Pharmaceuticals, Inc., a publicly traded, specialty pharmaceutical company engaged in the development and commercialization of proprietary prescription products.  During his approximately twelve years at Kos, Mr. Rodriguez held various positions of increasing responsibility, including serving as Interim Chief Financial Officer and finally serving as Senior Vice President, Controller and Corporate Administration.  Prior to joining Kos, Mr. Rodriguez was employed by Arthur Andersen LLP from 1991 to 1994.  He is a Certified Public Accountant and obtained his Bachelor of Accounting from Florida International University.